Immune cells engineered to attack childhood cancers were able to eradicate different types of pediatric tumors in mice, according to a new study from the Stanford University School of Medicine.
The study, which was published online Jan. 17 in Clinical Cancer Research, provides evidence that these engineered cells can target many types of pediatric solid tumors, including brain tumors. Better treatments are badly needed for children with these tumors, particularly when traditional therapies fail.
“The prognosis for children with relapsed brain tumors or solid tumors or metastatic disease generally is dismal,” said Robbie Majzner, MD, the lead author of the new study and an instructor in pediatrics at Stanford. “We’re excited that we have a potential therapeutic representing a completely new modality to treat these children.” The study’s senior author is Crystal Mackall, MD, the Ernest and Amelia Gallo Family Professor and a professor of pediatrics and of medicine.
Immunotherapies that work well for adult cancers do not always succeed against childhood cancers, Majzner noted. One approach, called checkpoint inhibition, targets gene mutations that are limited in most pediatric cancers.
Another immunotherapy method, using chimeric antigen receptor T cells, or CAR-T cells, is the basis of a treatment for one form of relapsed childhood leukemia. Leukemia is a type of blood cancer. That therapy, tisagenlecleucel (brand name Kymriah), employs synthetic biology to make immune cells that react to a surface marker found on the leukemia cells.
Majzner and his colleagues decided to try to make CAR-T cells for pediatric brain tumors and solid tumors, including tumors found in bone and muscle. These cancers do not carry the same surface markers as leukemia, so the scientists’ first step was to look for another marker that engineered immune cells could target.
“You need high amounts of the target on the tumor cells, and you may need the target to be on every cell in a tumor,” Majzner said. The ideal surface marker must not be highly expressed on healthy tissue, to prevent engineered immune cells from attacking normal tissues.
The researchers screened 388 pediatric tumor samples for expression of a surface marker called B7-H3, which prior studies suggested might be a good candidate. B7-H3 was found on 84 percent of the samples, and it was present at high levels in 70 percent of samples. Many types of pediatric cancer were found to express high levels of B7-H3, including Ewing sarcoma (bone), rhabdomyosarcoma (muscle), Wilms tumor (kidneys), neuroblastoma (nerve cells) and medulloblastoma (brain).
The fact that the same marker exists across so many tumor types increases the chance that it could serve as the basis for a commercially viable therapy, Majzner said. Each tumor is fairly rare, with a few hundred children affected across the United States each year, but together they form a larger patient population.
‘The tumor just goes away’
The scientists then developed six types of CAR-T cells to target B7-H3 and tested them in a dish. The type of B7-H3 CAR-T cells that performed best was used for further studies.
The researchers tested these B7-H3 CAR-T cells against several xenograft models of pediatric cancer, in which human tumors were implanted in mice. In mice with osteosarcoma or Ewing sarcoma — both bone tumors — B7-H3 CAR-T cells eradicated the tumors. The treated mice lived significantly longer than animals that received a control treatment.
“The tumor just goes away,” Majzner said. “It’s very consistent. It happened in all the mice, and that’s exciting.”
A group of mice with osteosarcoma had their initial tumors surgically removed and then received B7-H3 CAR-T cells to test whether the cells could treat cancer cells that had spread to the lungs. Again, the CAR-T cells worked; the treated mice lived significantly longer than those in a control group.
The researchers also tested B7-H3 CAR-T cells in mice implanted with a pediatric brain tumor called medulloblastoma. The CAR-T cells were injected into the blood and were able to cross the blood-brain barrier and eradicate the tumors.
The researchers showed that B7-H3 CAR-T cells do not attack cells expressing low levels of B7-H3, a reassuring finding since some healthy cells produce low levels of the marker.
“We’re hopeful that there may be a therapeutic window of B7-H3 levels between tumor tissue and normal tissue,” Majzner said. “The only way to find out is to test our new CAR-T cells in clinical trials.”
Clinical trials planned
The team is now planning a series of phase-1 clinical trials for the B7-H3 CAR-T cells, starting with adult brain tumor patients. B7-H3 is not expressed on healthy tissues in the central nervous system, making it a good starting point for human trials.
The risk exists that the treatment may leave behind a few rare cancer cells that do not carry B7-H3, which could cause a relapse, Majzner noted. “We’re already making combination CAR cells that combine several targets and optimizing those for future clinical trials,” he said.
The study’s other Stanford authors are postdoctoral scholars Johanna Theruvath, MD, and Sabine Heitzeneder, MD; MD-PhD student Christopher Mount; life science researchers Skyler Rietberg and Peng Xu; graduate students Miles Linde and Louai Labanieh; senior research scientist Elena Sotillo, PhD; former senior research scientist Siddhartha Mitra, PhD; Ravindra Majeti, MD, PhD, professor of medicine; and Michelle Monje, MD, PhD, associate professor of neurology.
Majzner is a member of the Stanford Cancer Institute. Majeti, Monje and Mackall are members of Stanford Bio-X, the Stanford Maternal & Child Health Research Institute and the Stanford Cancer Institute. Majeti and Monje are also members of the Stanford Institute for Stem Cell Biology and Regenerative Medicine, and Monje is a member of the Wu Tsai Neurosciences Institute at Stanford. Mackall is director of the Parker Institute for Cancer Immunotherapy at Stanford and founding director of the Stanford Center for Cancer Cell Therapy.
Researchers at the University of Colorado-Denver, the National Cancer Institute, the University of Virginia, the University of Washington, the University of Pittsburgh, the University of British Columbia, the British Columbia Cancer Research Center, the British Columbia Cancer Agency, MacroGenics Inc., the Children’s Hospital of Philadelphia and the University of Pennsylvania also contributed to the study.
Mackall and some of the co-authors at other institutions hold patents on the use of B7-H3 CAR-T cells for cancer immunotherapy, as well as on anti-B7-H3 antibodies and single chain variable fragments. Mackall is a founder of and holds equity in Lyell Immunopharma.
The research was funded by the National Cancer Institute, the Sarcoma Alliance for Research Through Collaboration, Hyundai Hope on Wheels, the St. Baldrick’s Foundation and Stand Up 2 Cancer.
To read more Press Release articles, click here.